LensGen® Receives IDE Approval from the U.S. FDA to Begin Clinical Study of the Juvene® Presbyopia-Correcting Intraocular Lens

IRVINE, Calif., Nov. 29, 2021 /PRNewswire/ — LensGen, Inc., a privately held ophthalmic medical device company, announced today that it has received approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal study of the company’s Juvene intraocular lens (IOL) for patients with cataracts. The LensGen Juvene IOL is designed to permanently restore clear and continuous vision at all distances including near and intermediate. The lens is modular and has a fluid optic component that changes shape to adjust focus on demand for today’s active lifestyles, from viewing mobile devices and computer screens

OIS Podcast – Ram Rao, CEO LensGen – Never Taking No For An Answer

LensGen CEO, Ramgopal Rao Featured in OIS Podcast. “Ram tells his story from the early beginning while collaborating with the late, great Roger Steinert, MD and realizing that they had to go back to the drawing board to reinvent the technology. Rather than throw in the towel after hearing no repetitively from investors, Ram persevered at all costs, subsequently raised $42M to date and emerged with a breakthrough technology to treat cataracts and presbyopia. Listen in for pearls of entrepreneurial wisdom and understand why Ram never took no for an answer.”

LensGen® Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directors

Irvine, Calif., August 20, 2020 – LensGen, Inc., an ophthalmic medical device company and developer of Juvene®, a disruptive fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment, announces the initial Closing of a $10 million of the $20 million Bridge Financing. The company is also pleased to announce the election of James (Jim) Mazzo to its Board of Directors. The financing was led by the corporate venture investment arm of HOYA Group and is part of a larger Series B Financing planned in early 2021 that will fund the company through approval of Juvene IOL pivotal FDA study. “We


Prof. Dr. Thomas Kohnen to Share Interim “Grail” Study Results at ESCRS in Paris IRVINE, Calif., September 10, 2019 — LensGen®, Inc. will be featured in several activities as the European Society for Cataract and Refractive Surgery (ESCRS) event in Paris, France begins. LensGen developed Juvene™, which is the world’s first modular fluid optic IOL that uses biomimetic design principles to emulate the natural crystalline lens and provide a continuous dynamic range of vision from distance to near with high quality optics. On September 12, at the Ophthalmic Future Forums, Sumit Garg, M.D. will present an update of clinical data

LensGen® Will Present Early Results Of International “Grail” Study At ASCRS

Eric Donnenfeld M.D. Chosen for Prestigious Innovators Lecture News provided by LensGen, Inc. Apr 30, 2019, 09:15 ET IRVINE, Calif., April 30, 2019 /PRNewswire/ — LensGen®, Inc., a private California-based company focused on bringing to market Juvene™, a potentially game changing presbyopia-correcting intraocular lens (IOL) for the treatment of cataracts and presbyopia, will share results from its “Grail” Study at the ASCRS annual meeting in San Diego May 3-7. The results will include the latest available data on patients who have been treated at two international sites.   Juvene is the world’s first modular fluid optic IOL that uses biomimetic

LensGen® adds internationally recognized researcher and expert in anterior segment surgery, Sumit Garg, M.D., to its Scientific Advisory Board

Dr. Sumit (Sam) Garg is Vice Chair of Clinical Ophthalmology, Medical Director, and an Associate Professor in Cataract, Refractive, External Disease and Corneal Surgery at the Gavin Herbert Eye Institute at the University of California, Irvine. Dr. Garg is a highly-skilled clinician, surgeon, and teacher, and has expertise in cataract surgery and complication management, corneal (PKP, FLEK, DSEK, DMEK), conjunctival, and refractive surgery. Dr. Garg participates in numerous research projects, many of which he has presented at national and international meetings. In addition to his research activities, Dr. Garg has authored numerous peer-reviewed papers and book chapters. Dr. Garg currently

LensGen® Announces Funding and Patent Success

IRVINE, Calif., July 17, 2018 /PRNewswire/ — LensGen®, Inc., a private California company developing the world’s first modular, fluid-optic, curvature changing intraocular lens (IOL) is reporting significant progress in its effort to transform how presbyopia is addressed. The Company successfully achieved a key clinical performance milestone which triggered the release of $11 million in funding as part of the Series A Financing that was announced in May 2017. Also, lead investor HOYA Group opted to invest an additional $4.4M that was an available option in the Series A financing. “We are pleased that LensGen is continuing to make outstanding progress

LensGen® Adds Leading Cataract and Refractive Surgeon, Opinion Leader and Past ASCRS President, Kerry D. Solomon, M.D., to its Scientific Advisory Board

Kerry D. Solomon, MD Cataract, LASIK and advanced vision correction specialist at the Carolina Eyecare Physicians; Director of the Carolina Eyecare Research Institute; Clinical Professor of Ophthalmology at the Medical University of South Carolina (MUSC). Dr. Solomon is an international recognized expert in cataract and refractive surgery and 2016 President of the American Society of Cataract and Refractive Surgeons (ASCRS). Over his 24 years of practicing medicine, Dr. Solomon has achieved status among the country’s best ophthalmic surgeons. He was one of the first in the country to perform laser-assisted cataract surgery, implant multifocal and astigmatic correction lenses, and perform

LensGen® Closes $21 Million Series A Financing to Advance Modular, Fluid-Optic Accommodating Intraocular Lens

Irvine, Ca. May 1, 2017—LensGen, Inc., a private company developing Juvene ™, the world’s first modular, fluid-optic accommodating intraocular lens, has closed a $21 million Series A financing. The financing was led by the corporate venture investment arm of HOYA Group and included participation from Relativity Healthcare Partners. The financing includes an option to expand the financing commitment by an additional $5 million. “We are pleased to attract an experienced ophthalmology and corporate strategic investor like HOYA to accelerate our efforts to further develop and bring to market this innovative and elegant lens solution for treating presbyopia,” said Ramgopal Rao,

LensGen® Announces New Members to Scientific Advisory Board

February 2016 LensGen® adds two prominent ophthalmic surgeon thought leaders to its exceptional medical advisory team: Eric Donnenfeld, MD Founding Partner Ophthalmic Consultants of Long Island Clinical Professor of Ophthalmology NYU Dr. Donnenfeld is an internationally recognized expert and pioneer in refractive, cornea and cataract surgery and one of the leading refractive and cataract surgeons in the United States. Dr. Donnenfeld is a past President of the American Society of Cataract and Refractive Surgery. He has authored more than 180 papers on cornea, external disease, cataract and refractive surgery, 500 scientific articles, and 40 books and book chapters on subjects